A	a	O	O	O	O
phase	phase	O	O	O	O
II	ii	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
advanced	advanced	O	O	O	O
metastatic	metastatic	O	O	O	O
renal	renal	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

OBJECTIVES	objectives	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
activity	activity	O	O	O	O
of	of	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
metastatic	metastatic	O	O	O	O
renal	renal	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
to	to	O	O	O	O
measure	measure	O	O	O	O
changes	changes	O	O	O	O
of	of	O	O	O	O
one	one	O	O	O	O
angiogenic	angiogenic	O	O	O	O
factor	factor	O	O	O	O
,	,	O	O	O	O
vascular	vascular	O	O	O	O
endothelial	endothelial	O	O	O	O
growth	growth	O	O	O	O
factor	factor	O	O	O	O
(VEGF)165	(vegf)165	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
AND	and	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
29	29	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
enrolled	enrolled	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
using	using	O	O	O	O
an	an	O	O	O	O
intra-patient	intra-patient	O	O	O	O
dose	dose	O	O	O	O
escalation	escalation	O	O	O	O
schedule	schedule	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
began	began	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
400	400	O	O	O	O
mg/d	mg/d	O	O	O	O
and	and	O	O	O	O
escalated	escalated	O	O	O	O
as	as	O	O	O	O
tolerated	tolerated	O	O	O	O
to	to	O	O	O	O
1200	1200	O	O	O	O
mg/d	mg/d	O	O	O	O
by	by	O	O	O	O
day	day	O	O	O	O
54	54	O	O	O	O
.	.	O	O	O	O

Fifty-nine	fifty-nine	O	O	O	O
per	per	O	O	O	O
cent	cent	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
had	had	O	O	O	O
previous	previous	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
IL-2	il-2	O	O	O	O
and	and	O	O	O	O
52	52	O	O	O	O
%	%	O	O	O	O
were	were	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
2	2	O	O	O	O
or	or	O	O	O	O
3	3	O	O	O	O
.	.	O	O	O	O

Systemic	systemic	O	O	O	O
plasma	plasma	O	O	O	O
VEGF165	vegf165	O	O	O	O
levels	levels	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
by	by	O	O	O	O
dual	dual	O	O	O	O
monoclonal	monoclonal	O	O	O	O
ELISA	elisa	O	O	O	O
in	in	O	O	O	O
8	8	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
24	24	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
evaluable	evaluable	O	O	O	O
for	for	O	O	O	O
response	response	O	O	O	O
with	with	O	O	O	O
one	one	O	O	O	O
partial	partial	O	O	O	O
response	response	O	O	O	O
of	of	O	O	O	O
11	11	O	O	O	O
months	months	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
hepatic	hepatic	O	O	O	O
and	and	O	O	O	O
pulmonary	pulmonary	O	O	O	O
metastases	metastases	O	O	OTHERS	I
(	(	O	O	O	O
4	4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
one	one	O	O	O	O
minor	minor	O	O	O	O
response	response	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
2	2	O	O	O	O
patients	patients	O	O	O	O
stable	stable	O	O	O	O
for	for	O	O	O	O
over	over	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

Somnolence	somnolence	O	DISEASE	OTHERS	I
and	and	O	O	O	O
constipation	constipation	O	DISEASE	OTHERS	I
were	were	O	O	O	O
prominent	prominent	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
and	and	O	O	O	O
most	most	O	O	O	O
patients	patients	O	O	O	O
could	could	O	O	O	O
not	not	O	O	O	O
tolerate	tolerate	O	O	O	O
the	the	O	O	O	O
1200	1200	O	O	O	O
mg/day	mg/day	O	O	O	O
dose	dose	O	O	O	O
level	level	O	O	O	O
.	.	O	O	O	O

Systemic	systemic	O	O	O	O
plasma	plasma	O	O	O	O
VEGF165	vegf165	O	O	O	O
levels	levels	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
change	change	O	O	O	O
with	with	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
These	these	O	O	O	O
results	results	O	O	O	O
are	are	O	O	O	O
consistent	consistent	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
low	low	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
activity	activity	O	O	O	O
of	of	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
renal	renal	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Administration	administration	O	O	O	O
of	of	O	O	O	O
doses	doses	O	O	O	O
over	over	O	O	O	O
800	800	O	O	O	O
mg/day	mg/day	O	O	O	O
was	was	O	O	O	O
difficult	difficult	O	O	O	O
to	to	O	O	O	O
achieve	achieve	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
population	population	O	O	O	O
,	,	O	O	O	O
however	however	O	O	O	O
lower	lower	O	O	O	O
doses	doses	O	O	O	O
were	were	O	O	O	O
practical	practical	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
dose-response	dose-response	O	O	O	O
relationship	relationship	O	O	O	O
,	,	O	O	O	O
if	if	O	O	O	O
any	any	O	O	O	O
,	,	O	O	O	O
of	of	O	O	O	O
thalidomide	thalidomide	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
renal	renal	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
is	is	O	O	O	O
unclear	unclear	O	O	O	O
.	.	O	O	O	O

